EODData

MEMBERSHIP REGISTER LOG IN

FRA, C17: Corvus Pharmaceuticals Inc

22 Dec 2025
LAST:

6.270

CHANGE:
 0.11		OPEN:
6.270		HIGH:
6.270		ASK:
0.000		VOLUME:
0
CHG(%):
1.72		PREV:
6.380		LOW:
6.270		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 Dec 256.2706.2706.2706.2700
19 Dec 256.3806.3806.3806.3800
18 Dec 256.5406.5406.5406.5400
17 Dec 256.6506.6506.6506.6500
16 Dec 256.9906.9906.9906.9900
15 Dec 257.0307.0307.0307.0300
12 Dec 257.0507.0507.0507.0500
11 Dec 257.1107.1107.1107.1100
10 Dec 257.3307.3307.3307.3300
09 Dec 257.3907.3907.3907.3900

PROFILE

Name:Corvus Pharmaceuticals Inc
About:Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:901 Gateway Boulevard, South San Francisco, CA, United States, 94080
Website:https://www.corvuspharma.com
ISIN:US2210151005
LEI:549300I3AVJ8F75NCX65

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-6.27 
Forward P/E:-7.21 
PEG Ratio:-0.15 
Price to Book:6.03 
Return on Assets:-0.29 
Return on Equity:-0.69 
EBITDA:5.13M 
Shares:74.51M 
Market Cap:467.2M 

TECHNICAL INDICATORS

MA5:6.574.7%
MA10:6.879.6%
MA20:7.1514.0%
MA50:6.859.3%
MA100:5.876.9%
MA200:4.5936.7%
RSI14:29.20 
WPR14:-100.00 
MTM14:-0.57
ROC14:-0.08 
ATR:0.16 
Week High:7.0312.1%
Week Low:6.270.0%
Month High:7.7623.8%
Month Low:6.2736.7%
Year High:7.7723.9%
Year Low:2.35166.9%
Volatility:29.91